Sugi Predict

Sugi Predict / Targets / GSTP1

GSTP1

Glutathione S-transferase P · P09211 · GSTP1 on Sugi Atlas →

22,617 patent compounds predicted against GSTP1, 12,603 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL300204 SCHEMBL300204 0.82 20/20
SCHEMBL761344 SCHEMBL761344 1.00 19/20
SCHEMBL296538 SCHEMBL296538 0.58 18/20
SCHEMBL296539 SCHEMBL296539 0.58 18/20
SCHEMBL296944 SCHEMBL296944 0.77 17/20
SCHEMBL301085 SCHEMBL301085 0.57 17/20
SCHEMBL297913 SCHEMBL297913 1.00 16/20
SCHEMBL298137 SCHEMBL298137 0.72 16/20
SCHEMBL314096 SCHEMBL314096 0.78 15/20
Ethacrynic Acid Ethacrynic Acid (SCHEMBL42210) 0.76 15/20
SCHEMBL297980 SCHEMBL297980 0.75 15/20
SCHEMBL313019 SCHEMBL313019 0.67 15/20
SCHEMBL313295 SCHEMBL313295 0.63 15/20
SCHEMBL312767 SCHEMBL312767 0.60 15/20
Ethacrynic Acid Ethacrynic Acid (SCHEMBL26353) 1.00 14/20
Ethacrynic Acid Ethacrynic Acid (SCHEMBL905726) 0.97 14/20
SCHEMBL297920 SCHEMBL297920 0.75 14/20
SCHEMBL296537 SCHEMBL296537 0.52 14/20
SCHEMBL296924 SCHEMBL296924 0.60 13/20
SCHEMBL131795 SCHEMBL131795 0.44 13/20

Clinical trials — most relevant to GSTP1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Cysteine Supplementation in Critically Ill Neonates PHASE2/PHASE3UNKNOWN
Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma PHASE3COMPLETED
Paracetamol Toxicity in Septic Patients PHASE3SUSPENDED
Effect of Gamma Tocopherol Enriched Supplementation on Response to Inhaled O3 Exposure PHASE2COMPLETED
Prevent Cardiac Surgery Associated AKI Trial PHASE2RECRUITING
Effect of Gamma Tocopherol Enriched Supplementation on Response to Inhaled LPS PHASE1/PHASE2COMPLETED
Effect of Melatonin in Patients With Diabetic Peripheral Neuropathy PHASE2RECRUITING
Neoadjuvant Chemoradiotherapy Followed By Surgery in Treating Patients With Limited-Stage Small Cell Lung Cancer PHASE1COMPLETED
Pharmacokinetics, Metabolism and Analgesic Effects of Flupirtine PHASE1COMPLETED
Celecoxib in Preventing Colorectal Cancer in Young Patients With a Genetic Predisposition for Familial Adenomatous Polyposis PHASE1COMPLETED
Phase I Study of GST-HG151 Tablets in Healthy Volunteers PHASE1UNKNOWN
A Dose Escalation Trial of Radiation Therapy (RT) for Hepatocellular Carcinoma (HCC) PHASE1UNKNOWN
Safety, Tolerability and Pharmacokinetic Characteristics Evaluation on GST-HG121 Tablets PHASE1UNKNOWN
Pharmacokinetics and Safety of GST-HG171 Tablets in Subjects With Impaired and Normal Liver Function PHASE1COMPLETED
Safety, Tolerability and Pharmacokinetic Characteristics Evaluation on GST-HG171 Tablets PHASE1COMPLETED
Studying Urine and Blood Samples in Women With Newly Diagnosed Breast Cancer nanCOMPLETED
The Conversion of ENcapsulated GlucorAphanin, Gut Microbiota Phylogeny and gEnotype Study (ENGAGE) nanCOMPLETED
Cancer and Hearing Loss Related in Children nanCOMPLETED
S8516-S8736-S9125-S9240 Research Study of Genes in Tissue Samples From Patients With B-cell Non-Hodgkin Lymphoma nanCOMPLETED
APAP Hepatotoxicity After Therapeutic Doses nanUNKNOWN
Broccoli and Vascular Health Study nanCOMPLETED
Effects of Green Tea Extract (GTE) on Systemic Oxidative and Antioxidative Status in Chinese Patients With Stable Asthma nanCOMPLETED
Effect of Sulfur Amino Acid Depletion and Acetaminophen on Plasma Glutatione nanCOMPLETED
The Effect of Broccoli Sprouts as a Nutritional Supplement in the Prevention of Cardiovascular Disease nanCOMPLETED
Mechanisms of Response to Diesel Exhaust in Subjects With Asthma nanWITHDRAWN
Polymorphisms and Busulfan Pharmacokinetic Study nanUNKNOWN
Factors in Childhood Lung Susceptibility to Pollution nanCOMPLETED
Personalizing Preterm Neonatal Transfusions With Fetal Hemoglobin-Enriched Cord Blood nanNOT_YET_RECRUITING
Role of Cytochrome P450 2D6 (CYP2D6) *4 Polymorphism,in Malignant Breast Diseases nanCOMPLETED
Dietary and Genetic Factors in Asthma & Chronic Bronchitis in a Cohort of Chinese Singaporeans nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a GSTP1 binder may also engage these)

ProteinNameSimilarity
Q28514 — 1.000 Q28514 →
P28801 — 1.000 P28801 →
Q5R8R5 — 1.000 Q5R8R5 →
Q9TTY8 — 0.997 Q9TTY8 →
P19157 — 0.992 P19157 →
P46424 — 0.992 P46424 →
Q60550 — 0.991 Q60550 →
P04906 — 0.990 P04906 →
P47954 — 0.983 P47954 →
P80031 — 0.982 P80031 →
P46425 — 0.981 P46425 →
CBR1 Carbonyl reductase [NADPH] 1 0.914 landscape →
Q5NVN7 — 0.912 Q5NVN7 →
SAE1 SUMO-activating enzyme subunit 1 0.911 landscape →
Q67FW5 — 0.909 Q67FW5 →
Q4R3I0 — 0.906 Q4R3I0 →
A2VE14 — 0.905 A2VE14 →
Q8BGB7 — 0.903 Q8BGB7 →
Q27HK4 — 0.903 Q27HK4 →
Q58CY6 — 0.901 Q58CY6 →
B2GV54 — 0.900 B2GV54 →
Q86XW9 — 0.900 Q86XW9 →
Q6AXQ0 — 0.900 Q6AXQ0 →
A9CQL8 — 0.900 A9CQL8 →
Q6GV29 — 0.899 Q6GV29 →
Q9UHY7 — 0.899 Q9UHY7 →
Q8MI29 — 0.898 Q8MI29 →
Q9R1T2 — 0.897 Q9R1T2 →
D3ZVR7 — 0.896 D3ZVR7 →
Q5RCU5 — 0.896 Q5RCU5 →